Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Core Insights - Coherus BioSciences announced interim data from its Phase 1 clinical trial of CHS-114, a selective anti-CCR8 antibody, which will be presented at the 2025 AACR Annual Meeting [1][2] - The trial evaluates CHS-114 both as a monotherapy and in combination with toripalimab for patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) [1][2] Company Overview - Coherus BioSciences is a commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a growing revenue stream [4] - The company is focused on expanding the use of LOQTORZI in nasopharyngeal carcinoma and developing new indications in combination with its pipeline candidates [4] Clinical Trial Details - The Phase 1 study (NCT05635643) is designed to optimize the dosing of CHS-114 and assess its safety in advanced solid tumors, including HNSCC [2][3] - The study includes multiple cohorts, with Cohort 1a enrolling 20 patients and evaluating various doses of CHS-114, while Cohort 1b focuses on HNSCC patients with paired tumor biopsies [2] Product Information - CHS-114 is an afucosylated, cytolytic CCR8 monoclonal antibody that targets CCR8+ Tregs in the tumor microenvironment, aiming to enhance the immune response against tumors [3] - Preclinical studies have shown that CHS-114 can reduce tumor growth and improve antitumor activity when combined with anti-PD-1 treatment [3] Pipeline and Future Directions - Coherus has a robust immuno-oncology pipeline, including candidates like casdozokitug, which is being evaluated in multiple clinical studies [5] - The company is also planning to divest its UDENYCA franchise, with the transaction expected to close in early to mid-2025 [6]